👪

Inheritance

1

Autosomal Dominant HP:0000006

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:32115705 SUPPORT Human Clinical

"Gain-of-function mutations in the RYR2 gene are found in about 95% of patients with a genetically confirmed diagnosis of CPVT (Pérez-Riera et al. 2018) and are designated as CPVT type 1 (CPVT1). CPVT1 is autosomal-dominant"

Directly states that RYR2-associated CPVT (CPVT1) follows autosomal dominant inheritance.

⚙

Pathophysiology

6

RYR2 Gain-of-Function Variant

The upstream trigger of RYR2-CPVT is a pathogenic gain-of-function variant in RYR2, the gene encoding the cardiac ryanodine receptor calcium-release channel. Such variants sensitize RyR2 to sarcoplasmic-reticulum luminal calcium and increase the probability of spontaneous channel opening, predisposing to diastolic calcium release. RYR2 gain-of-function variants account for the large majority of genetically confirmed CPVT.

cardiomyocyte link

RYR2 link

ryanodine-sensitive calcium-release channel activity link ↑ INCREASED

heart link

Downstream

RYR2 Gain-of-Function Calcium Leak The gain-of-function variant sensitizes RyR2 to sarcoplasmic-reticulum luminal calcium, producing diastolic calcium leak.

Show evidence (1 reference)

PMID:32115705 SUPPORT Other

"Gain-of-function mutations in the RYR2 gene are found in about 95% of patients with a genetically confirmed diagnosis of CPVT"

Identifies gain-of-function RYR2 variants as the predominant genetic cause and upstream trigger of CPVT.

RYR2 Gain-of-Function Calcium Leak

Gain-of-function pathogenic variants in RYR2 cause aberrant calcium release (calcium leak) from the sarcoplasmic reticulum during diastole. During adrenergic stimulation (exercise or stress), beta-adrenergic signalling increases SR calcium loading and RyR2 phosphorylation, which in mutant channels leads to unregulated pathological calcium release into the cytosol.

cardiomyocyte link

RYR2 link

release of sequestered calcium ion into cytosol by sarcoplasmic reticulum link ↑ INCREASED calcium ion transport link ↑ INCREASED

ryanodine-sensitive calcium-release channel activity link

heart link

Downstream

Delayed After-Depolarizations Excess cytosolic calcium is extruded by the sodium-calcium exchanger (NCX), generating a depolarizing inward sodium current that produces DADs.

Sinoatrial Node Dysfunction The same RyR2-driven diastolic calcium leak also impairs sinoatrial node function, producing low sinus rates that independently contribute to arrhythmia risk in CPVT.

Show evidence (2 references)

PMID:35222090 SUPPORT Other

"The most common cellular phenotype in CPVT is higher than normal cytoplasmic Ca2+ concentrations during diastole due to Ca2+ leak from the SR through mutant RyR2"

Establishes that diastolic SR calcium leak through mutant RyR2 is the hallmark cellular phenotype in CPVT.

PMID:32115705 SUPPORT Other

"the deadly arrhythmias are caused by unregulated 'pathological' calcium release from the sarcoplasmic reticulum (SR), the major calcium storage organelle in striated muscle"

Confirms that pathological SR calcium release is the mechanistic basis of CPVT arrhythmias.

Delayed After-Depolarizations

The sodium-calcium exchanger (NCX) attempts to restore normal cytosolic calcium by extruding calcium in exchange for sodium ions (3 Na+ per Ca2+). The resulting inward sodium current generates delayed after-depolarizations (DADs). When DADs reach action potential threshold, they trigger premature ventricular beats.

cardiomyocyte link

cardiac muscle cell action potential link ⚠ ABNORMAL cardiac conduction link ↕ DYSREGULATED

Downstream

Triggered Ventricular Arrhythmia DADs exceeding action potential threshold initiate premature ventricular beats that degenerate into bidirectional or polymorphic VT.

Show evidence (1 reference)

PMID:35222090 SUPPORT Other

"Arrhythmias are triggered when the surface membrane sodium calcium exchanger (NCX) lowers cytoplasmic Ca2+ by importing 3 Na+ ions to extrude one Ca2+ ion. The Na+ influx leads to delayed after depolarizations (DADs) which trigger arrhythmia when reaching action potential threshold."

Describes the DAD mechanism linking calcium overload to triggered arrhythmias; DADs reaching action potential threshold produce abnormal action potentials and dysregulated cardiac conduction (triggered beats).

Triggered Ventricular Arrhythmia

Triggered activity from DADs initiates bidirectional or polymorphic ventricular tachycardia, the signature arrhythmia of CPVT. The arrhythmia is characteristically provoked by adrenergic stimulation during exercise or emotional stress. If sustained, VT can degenerate into ventricular fibrillation and cardiac arrest.

cardiomyocyte link

cardiac conduction link ⚠ ABNORMAL

Downstream

Syncope and Sudden Cardiac Death Hemodynamic compromise from sustained VT or degeneration to ventricular fibrillation.

Show evidence (1 reference)

PMID:37558300 SUPPORT Human Clinical

"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion"

Defines the characteristic arrhythmia pattern in CPVT.

Sinoatrial Node Dysfunction

The RyR2-driven diastolic calcium leak also affects the sinoatrial node, where sinus node dysfunction and low sinus heart rates are well-documented in CPVT patients and animal models. Slow sinus rates prolong the diastolic interval, allowing spontaneous SR calcium release, and independently contribute to ventricular arrhythmia risk in CPVT.

cardiac pacemaker cell of sinoatrial node link

SA node cell action potential link ↓ DECREASED cardiac conduction link ↓ DECREASED

Downstream

Syncope and Sudden Cardiac Death Severe bradycardia and slow sinus rates reduce cerebral perfusion and independently raise arrhythmia and sudden-death risk in CPVT.

Show evidence (1 reference)

PMID:32115705 SUPPORT Other

"sinus node dysfunction is a hallmark of CPVT in patients and animal models"

Establishes sinoatrial node dysfunction as a recognized feature of CPVT, supporting the parallel pacemaker-dysfunction branch of the module.

Syncope and Sudden Cardiac Death

Sustained ventricular tachycardia causes hemodynamic compromise leading to syncope. Degeneration to ventricular fibrillation results in cardiac arrest and sudden cardiac death if not terminated. Untreated CPVT carries high mortality, with estimates of up to 30-50% by age 40.

Show evidence (1 reference)

PMID:32115705 SUPPORT Human Clinical

"Symptoms range from palpitations to cardiac arrest, with mortality rates between 30 and 50% in untreated individuals by age 40"

Documents the high mortality of untreated CPVT.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Cardiovascular 6

Bidirectional Ventricular Tachycardia VERY_FREQUENT Ventricular tachycardia (HP:0004756)

Show evidence (1 reference)

PMID:37558300 SUPPORT Human Clinical

"characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion"

Bidirectional VT is the hallmark arrhythmia of CPVT.

Syncope FREQUENT Syncope (HP:0001279)

Show evidence (1 reference)

PMID:32115705 SUPPORT Human Clinical

"If patients on maximally tolerated beta-blocker therapy continue to have syncope or recurrent sustained VT, treatment should be intensified"

Syncope is recognized as a key clinical presentation in CPVT patients, referenced in treatment escalation guidelines.

Sudden Cardiac Death FREQUENT Sudden cardiac death (HP:0001645)

Show evidence (1 reference)

PMID:39835466 SUPPORT Human Clinical

"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a devastating heritable channelopathy that can lead to sudden cardiac death in children and young adults"

Sudden cardiac death is a defining risk of CPVT.

Palpitations FREQUENT Palpitations (HP:0001962)

Show evidence (1 reference)

PMID:32115705 SUPPORT Human Clinical

"Symptoms range from palpitations to cardiac arrest"

Palpitations are part of the CPVT symptom spectrum.

Ventricular Fibrillation OCCASIONAL Ventricular fibrillation (HP:0001663)

Show evidence (1 reference)

PMID:32115705 SUPPORT Human Clinical

"stress-induced cardiac channelopathy that has a high mortality in untreated patients"

Ventricular fibrillation is the mechanism of sudden death in CPVT.

Cardiac Arrest FREQUENT Cardiac arrest (HP:0001695)

Show evidence (1 reference)

PMID:32115705 SUPPORT Human Clinical

"mortality rates between 30 and 50% in untreated individuals by age 40"

Cardiac arrest is a major cause of mortality in CPVT.

Nervous System 1

Epilepsy OCCASIONAL Seizure (HP:0001250)

Absorbed from G2P CPVT with intellectual disability (limited evidence). Some RYR2 variants are associated with neurological phenotypes including seizures and neurodevelopmental delay.

Show evidence (1 reference)

PMID:39835466 SUPPORT Human Clinical

"there is an increasing recognition of the extra-cardiac manifestations such as epilepsy, neurodevelopmental delay, and glucose homeostasis abnormalities in RyR2 variant carriers"

Epilepsy is an emerging extra-cardiac manifestation of RYR2 variants.

🧬

Genetic Associations

1

RYR2 gain-of-function variants (Causative)

Show evidence (3 references)

PMID:32115705 SUPPORT Human Clinical

"Gain-of-function mutations in the RYR2 gene are found in about 95% of patients with a genetically confirmed diagnosis of CPVT"

Establishes that RYR2 gain-of-function mutations account for the vast majority (~95%) of genetically confirmed CPVT cases.

PMID:35222090 SUPPORT Other

"Mutations in proteins involved in Ca2+ signaling can lead to catecholaminergic polymorphic ventricular tachycardia (CPVT)"

Confirms that calcium signalling protein mutations (primarily RYR2) cause CPVT.

CGGV:assertion_1da07a67-9d04-448b-843b-39dac372cb59-2021-01-20T050000.000Z SUPPORT Other

ClinGen classifies the RYR2-catecholaminergic polymorphic ventricular tachycardia gene-disease relationship as definitive with autosomal dominant inheritance.

💊

Treatments

4

Beta-Blocker Therapy (Nadolol)

Action: nadolol therapy Ontology label: Pharmacotherapy NCIT:C15986

Nonselective beta-blockers, particularly nadolol, are first-line therapy for CPVT. Nadolol is superior to beta1-selective agents in reducing exercise-induced ventricular arrhythmias. All patients with a clinical or genetic diagnosis of CPVT should receive beta-blocker therapy and avoid competitive sports and strenuous exercise.

Show evidence (1 reference)

PMID:26432584 SUPPORT Human Clinical

"The incidence and severity of ventricular arrhythmias decreased during treatment with nadolol compared with during treatment with β1-selective β-blockers"

Demonstrates nadolol superiority over selective beta-blockers in CPVT.

Flecainide

Action: flecainide therapy Ontology label: Pharmacotherapy NCIT:C15986

Flecainide is used as add-on therapy in patients with breakthrough arrhythmias on beta-blockers. It directly inhibits RyR2 by open state block, reducing the mass of calcium sparks and preventing arrhythmogenic calcium waves.

Show evidence (2 references)

PMID:19835880 SUPPORT In Vitro

"flecainide significantly reduced spark amplitude and spark width, resulting in a 40% reduction in spark mass"

Demonstrates the mechanism by which flecainide suppresses arrhythmogenic calcium waves in isolated cardiomyocytes from a CPVT mouse model.

PMID:19835880 SUPPORT Model Organism

"we recently found that the drug flecainide inhibits RyR2 channels and prevents CPVT in mice and humans"

Establishes flecainide as an effective CPVT therapy through RyR2 channel inhibition.

Implantable Cardioverter-Defibrillator (ICD)

Action: ICD implantation Ontology label: surgical procedure MAXO:0000004

ICD implantation is recommended for patients with inadequately controlled arrhythmias despite optimal pharmacotherapy, or survivors of cardiac arrest. ICD shocks can paradoxically trigger catecholamine surges and arrhythmia storms, so programming must be optimized.

Show evidence (1 reference)

PMID:39835466 SUPPORT Human Clinical

"Early genetic testing and personalized treatment, including beta-blockers, flecainide, and ICDs, is important in improving outcomes"

ICDs are part of the standard CPVT management toolkit.

Exercise Restriction

Action: exercise restriction Ontology label: supportive care MAXO:0000950

Avoidance of competitive sports and strenuous exercise is a cornerstone of CPVT management. Exercise provokes catecholamine release that triggers arrhythmias in susceptible individuals.

Show evidence (1 reference)

PMID:37558300 SUPPORT Human Clinical

"characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion"

Exercise provocation of arrhythmias is the basis for activity restriction recommendations.

{ }

Source YAML

click to show

name: RYR2 CPVT
creation_date: '2026-04-04T00:00:00Z'
updated_date: '2026-04-07T02:36:25Z'
description: >-
  RYR2-related catecholaminergic polymorphic ventricular tachycardia (CPVT) is a
  heritable cardiac channelopathy caused by gain-of-function pathogenic variants
  in the RYR2 gene encoding the cardiac ryanodine receptor. The hallmark is
  exercise- or emotion-triggered bidirectional or polymorphic ventricular
  tachycardia in the setting of a structurally normal heart and normal resting
  ECG. If untreated, mortality rates of 30-50% by age 40 have been reported.
  RYR2 variants are found in about 95% of patients with a genetically
  confirmed diagnosis of CPVT. Estimated prevalence is 1:5,000 to
  1:10,000. This entry absorbs 4 Gene2Phenotype rows for RYR2: definitive CPVT,
  limited CPVT with intellectual disability, refuted ARVC (noted only), and
  limited HCM (noted only).
synonyms:
- CPVT
- CPVT1
- catecholaminergic polymorphic ventricular tachycardia
- familial polymorphic ventricular tachycardia
category: Genetic
disease_term:
  preferred_term: catecholaminergic polymorphic ventricular tachycardia
  term:
    id: MONDO:0017990
    label: catecholaminergic polymorphic ventricular tachycardia
parents:
- Cardiac Arrhythmia
- Channelopathy
prevalence:
- population: Global
  percentage: Rare
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CPVT is rare, with an estimated prevalence of 1:5000 to 1:10,000 depending on the population studied"
    explanation: Provides prevalence estimate for CPVT in the general population.
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gain-of-function mutations in the RYR2 gene are found in about 95% of patients with a genetically confirmed diagnosis of CPVT (Pérez-Riera et al. 2018) and are designated as CPVT type 1 (CPVT1). CPVT1 is autosomal-dominant"
    explanation: Directly states that RYR2-associated CPVT (CPVT1) follows autosomal dominant inheritance.
pathophysiology:
- name: RYR2 Gain-of-Function Variant
  conforms_to: "cardiac_ion_channel_repolarization#Cardiac Ion-Channel or Calcium-Handling Variant"
  role: trigger
  description: >-
    The upstream trigger of RYR2-CPVT is a pathogenic gain-of-function variant
    in RYR2, the gene encoding the cardiac ryanodine receptor calcium-release
    channel. Such variants sensitize RyR2 to sarcoplasmic-reticulum luminal
    calcium and increase the probability of spontaneous channel opening,
    predisposing to diastolic calcium release. RYR2 gain-of-function variants
    account for the large majority of genetically confirmed CPVT.
  genes:
  - preferred_term: RYR2
    term:
      id: hgnc:10484
      label: RYR2
  molecular_functions:
  - preferred_term: ryanodine-sensitive calcium-release channel activity
    term:
      id: GO:0005219
      label: ryanodine-sensitive calcium-release channel activity
    modifier: INCREASED
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Gain-of-function mutations in the RYR2 gene are found in about 95% of patients with a genetically confirmed diagnosis of CPVT"
    explanation: Identifies gain-of-function RYR2 variants as the predominant genetic cause and upstream trigger of CPVT.
  downstream:
  - target: RYR2 Gain-of-Function Calcium Leak
    description: >-
      The gain-of-function variant sensitizes RyR2 to sarcoplasmic-reticulum
      luminal calcium, producing diastolic calcium leak.
- name: RYR2 Gain-of-Function Calcium Leak
  conforms_to: "cardiac_ion_channel_repolarization#Altered Action Potential and Calcium Handling"
  role: central_effector
  description: >-
    Gain-of-function pathogenic variants in RYR2 cause aberrant calcium release
    (calcium leak) from the sarcoplasmic reticulum during diastole. During
    adrenergic stimulation (exercise or stress), beta-adrenergic signalling
    increases SR calcium loading and RyR2 phosphorylation, which in mutant
    channels leads to unregulated pathological calcium release into the cytosol.
  genes:
  - preferred_term: RYR2
    term:
      id: hgnc:10484
      label: RYR2
  molecular_functions:
  - preferred_term: ryanodine-sensitive calcium-release channel activity
    term:
      id: GO:0005219
      label: ryanodine-sensitive calcium-release channel activity
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
    term:
      id: GO:0014808
      label: release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
    modifier: INCREASED
  - preferred_term: calcium ion transport
    term:
      id: GO:0006816
      label: calcium ion transport
    modifier: INCREASED
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:35222090
    reference_title: Molecular Changes in the Cardiac RyR2 With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common cellular phenotype in CPVT is higher than normal cytoplasmic Ca2+ concentrations during diastole due to Ca2+ leak from the SR through mutant RyR2"
    explanation: Establishes that diastolic SR calcium leak through mutant RyR2 is the hallmark cellular phenotype in CPVT.
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the deadly arrhythmias are caused by unregulated 'pathological' calcium release from the sarcoplasmic reticulum (SR), the major calcium storage organelle in striated muscle"
    explanation: Confirms that pathological SR calcium release is the mechanistic basis of CPVT arrhythmias.
  downstream:
  - target: Delayed After-Depolarizations
    description: Excess cytosolic calcium is extruded by the sodium-calcium exchanger (NCX), generating a depolarizing inward sodium current that produces DADs.
  - target: Sinoatrial Node Dysfunction
    description: The same RyR2-driven diastolic calcium leak also impairs sinoatrial node function, producing low sinus rates that independently contribute to arrhythmia risk in CPVT.
- name: Delayed After-Depolarizations
  conforms_to: "cardiac_ion_channel_repolarization#Arrhythmogenic Substrate and Triggered Activity"
  role: amplifier
  description: >-
    The sodium-calcium exchanger (NCX) attempts to restore normal cytosolic
    calcium by extruding calcium in exchange for sodium ions (3 Na+ per Ca2+).
    The resulting inward sodium current generates delayed after-depolarizations
    (DADs). When DADs reach action potential threshold, they trigger premature
    ventricular beats.
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cardiac muscle cell action potential
    term:
      id: GO:0086001
      label: cardiac muscle cell action potential
    modifier: ABNORMAL
  - preferred_term: cardiac conduction
    term:
      id: GO:0061337
      label: cardiac conduction
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:35222090
    reference_title: Molecular Changes in the Cardiac RyR2 With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Arrhythmias are triggered when the surface membrane sodium calcium exchanger (NCX) lowers cytoplasmic Ca2+ by importing 3 Na+ ions to extrude one Ca2+ ion. The Na+ influx leads to delayed after depolarizations (DADs) which trigger arrhythmia when reaching action potential threshold."
    explanation: Describes the DAD mechanism linking calcium overload to triggered arrhythmias; DADs reaching action potential threshold produce abnormal action potentials and dysregulated cardiac conduction (triggered beats).
  downstream:
  - target: Triggered Ventricular Arrhythmia
    description: DADs exceeding action potential threshold initiate premature ventricular beats that degenerate into bidirectional or polymorphic VT.
- name: Triggered Ventricular Arrhythmia
  conforms_to: "cardiac_ion_channel_repolarization#Ventricular Tachyarrhythmia"
  role: effector
  description: >-
    Triggered activity from DADs initiates bidirectional or polymorphic
    ventricular tachycardia, the signature arrhythmia of CPVT. The arrhythmia
    is characteristically provoked by adrenergic stimulation during exercise
    or emotional stress. If sustained, VT can degenerate into ventricular
    fibrillation and cardiac arrest.
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cardiac conduction
    term:
      id: GO:0061337
      label: cardiac conduction
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37558300
    reference_title: "Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion"
    explanation: Defines the characteristic arrhythmia pattern in CPVT.
  downstream:
  - target: Syncope and Sudden Cardiac Death
    description: Hemodynamic compromise from sustained VT or degeneration to ventricular fibrillation.
- name: Sinoatrial Node Dysfunction
  conforms_to: "cardiac_ion_channel_repolarization#Sinoatrial Node Pacemaker Dysfunction"
  role: effector
  description: >-
    The RyR2-driven diastolic calcium leak also affects the sinoatrial node,
    where sinus node dysfunction and low sinus heart rates are well-documented
    in CPVT patients and animal models. Slow sinus rates prolong the diastolic
    interval, allowing spontaneous SR calcium release, and independently
    contribute to ventricular arrhythmia risk in CPVT.
  cell_types:
  - preferred_term: cardiac pacemaker cell of sinoatrial node
    term:
      id: CL:1000477
      label: cardiac pacemaker cell of sinoatrial node
  biological_processes:
  - preferred_term: SA node cell action potential
    term:
      id: GO:0086015
      label: SA node cell action potential
    modifier: DECREASED
  - preferred_term: cardiac conduction
    term:
      id: GO:0061337
      label: cardiac conduction
    modifier: DECREASED
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "sinus node dysfunction is a hallmark of CPVT in patients and animal models"
    explanation: Establishes sinoatrial node dysfunction as a recognized feature of CPVT, supporting the parallel pacemaker-dysfunction branch of the module.
  downstream:
  - target: Syncope and Sudden Cardiac Death
    description: Severe bradycardia and slow sinus rates reduce cerebral perfusion and independently raise arrhythmia and sudden-death risk in CPVT.
- name: Syncope and Sudden Cardiac Death
  conforms_to: "cardiac_ion_channel_repolarization#Syncope and Sudden Cardiac Death"
  role: outcome
  description: >-
    Sustained ventricular tachycardia causes hemodynamic compromise leading to
    syncope. Degeneration to ventricular fibrillation results in cardiac arrest
    and sudden cardiac death if not terminated. Untreated CPVT carries high
    mortality, with estimates of up to 30-50% by age 40.
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms range from palpitations to cardiac arrest, with mortality rates between 30 and 50% in untreated individuals by age 40"
    explanation: Documents the high mortality of untreated CPVT.
phenotypes:
- category: Cardiovascular
  name: Bidirectional Ventricular Tachycardia
  description: >-
    Alternating-axis QRS complexes during ventricular tachycardia,
    pathognomonic for CPVT when triggered by exercise or catecholamine
    stimulation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ventricular tachycardia
    term:
      id: HP:0004756
      label: Ventricular tachycardia
  evidence:
  - reference: PMID:37558300
    reference_title: "Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion"
    explanation: Bidirectional VT is the hallmark arrhythmia of CPVT.
- category: Cardiovascular
  name: Syncope
  description: >-
    Transient loss of consciousness triggered by exercise or emotional stress,
    often the presenting symptom in childhood. Symptom onset typically occurs
    between ages 7 and 12 years.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If patients on maximally tolerated beta-blocker therapy continue to have syncope or recurrent sustained VT, treatment should be intensified"
    explanation: Syncope is recognized as a key clinical presentation in CPVT patients, referenced in treatment escalation guidelines.
- category: Cardiovascular
  name: Sudden Cardiac Death
  description: >-
    Sudden cardiac death from ventricular fibrillation, the most feared
    consequence of CPVT. Untreated CPVT carries high mortality.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sudden cardiac death
    term:
      id: HP:0001645
      label: Sudden cardiac death
  evidence:
  - reference: PMID:39835466
    reference_title: "Genetics, manifestations, and management of catecholaminergic polymorphic ventricular tachycardia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a devastating heritable channelopathy that can lead to sudden cardiac death in children and young adults"
    explanation: Sudden cardiac death is a defining risk of CPVT.
- category: Cardiovascular
  name: Palpitations
  description: >-
    Awareness of rapid or irregular heartbeat, often preceding more severe
    arrhythmic events.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Palpitations
    term:
      id: HP:0001962
      label: Palpitations
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms range from palpitations to cardiac arrest"
    explanation: Palpitations are part of the CPVT symptom spectrum.
- category: Cardiovascular
  name: Ventricular Fibrillation
  description: >-
    Chaotic electrical activity in the ventricles leading to hemodynamic
    collapse. Occurs when polymorphic VT degenerates.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ventricular fibrillation
    term:
      id: HP:0001663
      label: Ventricular fibrillation
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "stress-induced cardiac channelopathy that has a high mortality in untreated patients"
    explanation: Ventricular fibrillation is the mechanism of sudden death in CPVT.
- category: Cardiovascular
  name: Cardiac Arrest
  description: >-
    Abrupt cessation of cardiac function due to sustained ventricular
    fibrillation. A significant proportion of untreated patients experience
    cardiac arrest.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cardiac arrest
    term:
      id: HP:0001695
      label: Cardiac arrest
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mortality rates between 30 and 50% in untreated individuals by age 40"
    explanation: Cardiac arrest is a major cause of mortality in CPVT.
- category: Neurological
  name: Epilepsy
  description: >-
    Seizures and epilepsy have been reported in RYR2 variant carriers,
    representing extra-cardiac manifestations. This may reflect shared calcium
    signalling dysfunction in neuronal tissue.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39835466
    reference_title: "Genetics, manifestations, and management of catecholaminergic polymorphic ventricular tachycardia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "there is an increasing recognition of the extra-cardiac manifestations such as epilepsy, neurodevelopmental delay, and glucose homeostasis abnormalities in RyR2 variant carriers"
    explanation: Epilepsy is an emerging extra-cardiac manifestation of RYR2 variants.
  notes: >-
    Absorbed from G2P CPVT with intellectual disability (limited evidence).
    Some RYR2 variants are associated with neurological phenotypes including
    seizures and neurodevelopmental delay.
genetic:
- name: RYR2 gain-of-function variants
  association: Causative
  features: >-
    Gain-of-function mutations in RYR2 are found in about 95% of patients
    with a genetically confirmed diagnosis of CPVT. Variants cluster in
    four hot-spot regions of the protein. The resulting channel dysfunction
    leads to pathological diastolic calcium leak from the sarcoplasmic
    reticulum during adrenergic stimulation.
  gene_term:
    preferred_term: RYR2
    term:
      id: hgnc:10484
      label: RYR2
  evidence:
  - reference: PMID:32115705
    reference_title: Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gain-of-function mutations in the RYR2 gene are found in about 95% of patients with a genetically confirmed diagnosis of CPVT"
    explanation: Establishes that RYR2 gain-of-function mutations account for the vast majority (~95%) of genetically confirmed CPVT cases.
  - reference: PMID:35222090
    reference_title: Molecular Changes in the Cardiac RyR2 With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mutations in proteins involved in Ca2+ signaling can lead to catecholaminergic polymorphic ventricular tachycardia (CPVT)"
    explanation: Confirms that calcium signalling protein mutations (primarily RYR2) cause CPVT.
  - reference: CGGV:assertion_1da07a67-9d04-448b-843b-39dac372cb59-2021-01-20T050000.000Z
    reference_title: "RYR2 / catecholaminergic polymorphic ventricular tachycardia (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "RYR2 | HGNC:10484 | catecholaminergic polymorphic ventricular tachycardia | MONDO:0017990 | AD | Definitive"
    explanation: ClinGen classifies the RYR2-catecholaminergic polymorphic ventricular tachycardia gene-disease relationship as definitive with autosomal dominant inheritance.
treatments:
- name: Beta-Blocker Therapy (Nadolol)
  description: >-
    Nonselective beta-blockers, particularly nadolol, are first-line therapy
    for CPVT. Nadolol is superior to beta1-selective agents in reducing
    exercise-induced ventricular arrhythmias. All patients with a clinical
    or genetic diagnosis of CPVT should receive beta-blocker therapy and
    avoid competitive sports and strenuous exercise.
  treatment_term:
    preferred_term: nadolol therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:26432584
    reference_title: Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta1-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence and severity of ventricular arrhythmias decreased during treatment with nadolol compared with during treatment with β1-selective β-blockers"
    explanation: Demonstrates nadolol superiority over selective beta-blockers in CPVT.
- name: Flecainide
  description: >-
    Flecainide is used as add-on therapy in patients with breakthrough
    arrhythmias on beta-blockers. It directly inhibits RyR2 by open state
    block, reducing the mass of calcium sparks and preventing arrhythmogenic
    calcium waves.
  treatment_term:
    preferred_term: flecainide therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:19835880
    reference_title: Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "flecainide significantly reduced spark amplitude and spark width, resulting in a 40% reduction in spark mass"
    explanation: Demonstrates the mechanism by which flecainide suppresses arrhythmogenic calcium waves in isolated cardiomyocytes from a CPVT mouse model.
  - reference: PMID:19835880
    reference_title: Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we recently found that the drug flecainide inhibits RyR2 channels and prevents CPVT in mice and humans"
    explanation: Establishes flecainide as an effective CPVT therapy through RyR2 channel inhibition.
- name: Implantable Cardioverter-Defibrillator (ICD)
  description: >-
    ICD implantation is recommended for patients with inadequately controlled
    arrhythmias despite optimal pharmacotherapy, or survivors of cardiac
    arrest. ICD shocks can paradoxically trigger catecholamine surges and
    arrhythmia storms, so programming must be optimized.
  treatment_term:
    preferred_term: ICD implantation
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:39835466
    reference_title: "Genetics, manifestations, and management of catecholaminergic polymorphic ventricular tachycardia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early genetic testing and personalized treatment, including beta-blockers, flecainide, and ICDs, is important in improving outcomes"
    explanation: ICDs are part of the standard CPVT management toolkit.
- name: Exercise Restriction
  description: >-
    Avoidance of competitive sports and strenuous exercise is a cornerstone
    of CPVT management. Exercise provokes catecholamine release that triggers
    arrhythmias in susceptible individuals.
  treatment_term:
    preferred_term: exercise restriction
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:37558300
    reference_title: "Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by bidirectional or polymorphic ventricular arrhythmia provoked by exercise or emotion"
    explanation: Exercise provocation of arrhythmias is the basis for activity restriction recommendations.
notes: >-
  This entry lumps 4 Gene2Phenotype rows for RYR2. (1) CPVT definitive:
  the primary phenotype covered here. (2) CPVT with intellectual disability
  (limited): some RYR2 variants are associated with extracardiac neurological
  features including epilepsy and neurodevelopmental delay; these are captured
  in the phenotypes section. (3) ARVC (refuted): early reports suggested
  RYR2 variants could cause arrhythmogenic right ventricular cardiomyopathy,
  but this association has been refuted by subsequent studies and expert
  consensus. (4) HCM (limited): rare reports of hypertrophic cardiomyopathy
  in RYR2 variant carriers exist but evidence is very limited and not widely
  accepted.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 41 citations 2026-04-04T12:35:32.888865

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: RYR2 CPVT
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on RYR2 CPVT covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Research report: RYR2-mediated catecholaminergic polymorphic ventricular tachycardia (RYR2-CPVT / CPVT1)

Scope and evidence types

This report focuses on RYR2-mediated catecholaminergic polymorphic ventricular tachycardia (CPVT1), integrating 2023–2024 narrative reviews, pediatric observational cohorts/series, mechanistic structural/physiology studies, and ClinicalTrials.gov interventional trial records. Evidence sources here are aggregated disease-level resources (reviews and cohorts) rather than EHR-derived single-patient records, except where explicitly noted as case series. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2, lee2024treatmentoutcomesin pages 1-2, jurisic2023catecholaminergicpolymorphicventricular pages 1-2)

Disease name	Common synonyms / alternative names	Primary causal gene	Typical inheritance	Typical triggers	Key diagnostic test	Citation
RYR2-mediated catecholaminergic polymorphic ventricular tachycardia	CPVT; CPVT1; RYR2-CPVT; catecholaminergic polymorphic ventricular tachycardia type 1; RYR2-related CPVT	RYR2	Autosomal dominant	Exercise, acute emotional stress, catecholaminergic stimulation	Exercise stress test to provoke polymorphic/bidirectional ventricular arrhythmias; epinephrine challenge if exercise testing is not feasible	(aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 6-8, peltenburg2024prognosisandclinical pages 1-2)

Table: This table summarizes the core naming and identification fields for RYR2-mediated CPVT, including synonyms, causal gene, inheritance, triggers, and the principal diagnostic test. It is useful as a compact normalization artifact for a disease knowledge base entry.

1. Disease information

1.1 Concise overview (current understanding)

RYR2-mediated CPVT is an inherited cardiac arrhythmia syndrome characterized by adrenergically triggered ventricular arrhythmias—classically bidirectional or polymorphic ventricular tachycardia—occurring in the absence of structural heart disease and typically with a normal resting ECG. Clinical presentations include exercise- or emotion-triggered syncope and risk of sudden cardiac death. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

1.2 Identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The retrieved literature set did not include OMIM, Orphanet, MeSH, ICD-10/ICD-11, or MONDO identifier pages/records, so these identifiers cannot be verified or cited from primary database sources within the current tool context. (Evidence gap in retrieved documents.)

1.3 Synonyms/alternative names

Common synonyms include CPVT, CPVT1, RYR2-CPVT, and catecholaminergic polymorphic ventricular tachycardia type 1. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, peltenburg2024prognosisandclinical pages 1-2)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic or likely pathogenic variants in RYR2, encoding the cardiac ryanodine receptor (RyR2), a sarcoplasmic reticulum (SR) Ca2+ release channel. The dominant mechanism emphasized in recent reviews is RyR2 dysfunction leading to diastolic SR Ca2+ leak and triggered arrhythmias under catecholaminergic stimulation. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, peltenburg2024prognosisandclinical pages 1-2)

2.2 Risk factors

Genetic risk factors - Autosomal dominant inheritance is typical for RYR2-mediated CPVT. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4) - Variant class/type: Most pathogenic RYR2 variants associated with CPVT are missense and are described as gain-of-function (in one review, ~96% missense). (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4) - Penetrance: Reviews summarize high but incomplete penetrance for RYR2-mediated disease, approximately ~75–80%. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4) - De novo variants are described as common in some monogenic RYR2 cases and associated with earlier and more severe phenotypes. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, peltenburg2024prognosisandclinical pages 1-2)

Non-genetic/clinical risk factors (phenotype triggers) - Exercise and emotional stress are the dominant triggers, consistent with catecholamine-dependent arrhythmogenesis. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

2.3 Protective factors

Direct protective factors (genetic or environmental) were not explicitly identified/quantified in the retrieved sources.

2.4 Gene–environment interactions

A central, well-supported interaction is genotype (RYR2 dysfunction) × catecholaminergic environment (exercise/emotion, adrenergic stimulation) leading to arrhythmia provocation. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

3. Phenotypes

3.1 Core clinical phenotype spectrum (with onset, severity, progression)

Typical presentation: exertion- or emotion-triggered syncope; palpitations may occur; ventricular tachyarrhythmias can degenerate to ventricular fibrillation and sudden death. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)

Age of onset: pediatric predominance, with mean onset in one review 7–12 years and >60% experiencing their first syncope/cardiac arrest by age 20. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

Episodic nature: events are often episodic and triggered, rather than continuously progressive; however, untreated disease is described as highly lethal with substantial pre-diagnosis syncope/cardiac arrest burden. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

Atrial arrhythmias and sinus node dysfunction: RYR2 mutation carriers can present with broader rhythm phenotypes (including sinoatrial node dysfunction and atrial arrhythmias), particularly in children. (wang2024clinicalcharacteristicsand pages 7-8)

3.2 Frequency among affected individuals (recent study statistics)

In a 2024 Korean pediatric cohort (n=23), 73.9% developed cardiac events, 43.5% had aborted cardiac arrest, and 21.7% died during follow-up (mean follow-up 9.4±6.5 years). (lee2024treatmentoutcomesin pages 7-9)
In a 2023 Chinese pediatric cohort/review of 95 children, 13 deaths were reported during the disease course; RYR2 variants were 70.1% of genotyped cases (47/67). (yan2023clinicalandgenetic pages 1-2)

3.3 Suggested HPO terms (non-exhaustive)

Based on reported phenotypes and triggers in the retrieved sources: - Syncope — HP:0001279 (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, jurisic2023catecholaminergicpolymorphicventricular pages 1-2) - Sudden cardiac arrest — HP:0001695 (lee2024treatmentoutcomesin pages 7-9) - Ventricular tachycardia (polymorphic/bidirectional) — HP:0004756 (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2) - Premature ventricular contractions — HP:0001669 (peltenburg2024prognosisandclinical pages 1-2) - Atrial fibrillation/flutter — HP:0005110 / HP:0004799 (supported as atrial tachyarrhythmias occur in CPVT case series) (jurisic2023catecholaminergicpolymorphicventricular pages 1-2) - Sinus bradycardia / sinus node dysfunction — HP:0001688 / HP:0001642 (yan2023clinicalandgenetic pages 2-4, wang2024clinicalcharacteristicsand pages 7-8)

3.4 Quality of life impact

Quality-of-life impact is primarily mediated by exercise restriction, syncope risk, and ICD shock burden/psychological distress; LCSD is noted in review-level evidence as potentially improving quality of life by reducing events/shocks. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)

4. Genetic / molecular information

4.1 Causal gene(s)

RYR2 is the predominant causal gene for CPVT1, accounting for roughly ~60–70% of cases in review summaries; cohort data in Chinese children showed 70.1% of genetically positive tests were RYR2. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 2-4, yan2023clinicalandgenetic pages 1-2)

4.2 Variant characteristics

Variant type: predominantly missense (~96% per one review), described as gain-of-function. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)
Penetrance: review summaries estimate ~75–80% for RYR2-mediated disease. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)
Variant distribution: RYR2 pathogenic variants often cluster in three regions (N-terminal, central, C-terminal), though rare variants occur in healthy individuals, complicating interpretation. (peltenburg2024prognosisandclinical pages 1-2)

Variant classification: Some cohorts explicitly reference ACMG/AMP variant classification (pathogenic/likely pathogenic/VUS), indicating clinical use of standardized classification frameworks in CPVT workups. (lee2024treatmentoutcomesin pages 7-9)

4.3 Modifier genes / multiple variants

A review notes that multiple variants are an independent predictor of adverse events in CPVT risk modeling. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

4.4 Epigenetics / chromosomal abnormalities

No RYR2-CPVT–specific epigenetic or chromosomal abnormality evidence was identified in the retrieved sources.

5. Environmental information

5.1 Environmental and lifestyle factors

Adrenergic stimuli (exercise, emotional stress) are the key real-world triggers. Lifestyle recommendations and exercise modification are embedded in treatment algorithms and management considerations. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular media 56a4a30c)

5.2 Infectious agents

No infectious etiology is implicated for CPVT in the retrieved sources.

6. Mechanism / pathophysiology (causal chain, upstream vs downstream)

6.1 Canonical causal chain (current consensus)

Upstream trigger: catecholaminergic stimulation (exercise/emotion) increases adrenergic drive. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, peltenburg2024prognosisandclinical pages 1-2)

Molecular defect: RYR2 pathogenic variants predispose RyR2 to abnormal gating and diastolic SR Ca2+ leak. (peltenburg2024prognosisandclinical pages 1-2, keefe2023roleofca^2+ pages 8-9)

Downstream electrophysiology: increased cytosolic Ca2+ activates the sodium–calcium exchanger (NCX), generating net inward current that produces delayed afterdepolarizations (DADs) and triggered action potentials → ventricular ectopy → polymorphic/bidirectional VT → VF/sudden death. (peltenburg2024prognosisandclinical pages 1-2, keefe2023roleofca^2+ pages 8-9)

6.2 Upstream modulators and structural biology (2023–2024 developments)

RyR2 regulatory complex and phosphorylation: A 2023 review summarizes RyR2 regulation by PKA and CaMKII (e.g., CaMKII phosphorylation at S2814; PKA at S2808/2830) and links phosphorylation and disrupted regulatory binding (e.g., FKBP12.6/calstabin2) to increased RyR2 open probability and diastolic Ca2+ sparks/leak. (keefe2023roleofca^2+ pages 29-34, keefe2023roleofca^2+ pages 3-4)

Structural “primed” state and Rycal stabilization (2024): A 2024 Nature Communications structural study reports that CPVT-linked RyR2 variants and remodeled RyR2 in heart failure share a pathologic “primed” intermediate conformation associated with diastolic Ca2+ leak; “Rycal” drugs are described as reverting the primed state toward closed and reducing leak. The paper describes RyR2 channels as hyperphosphorylated/oxidized and depleted of calstabin-2 in heart failure, and frames a unified structural-physiological mechanism of leak across arrhythmogenic disorders. (miotto2024structuralbasisfor pages 1-2)

6.3 Suggested GO biological process / cellular component terms (examples)

Regulation of cardiac muscle contraction by calcium ion signaling — GO:0010881 (mechanistically central to RyR2 dysfunction and EC coupling) (keefe2023roleofca^2+ pages 29-34)
Ryanodine-sensitive calcium-release channel activity — GO:0005219 (RyR2 function) (peltenburg2024prognosisandclinical pages 1-2)
Calcium ion transport into cytosol — GO:0060402 (SR Ca2+ release) (peltenburg2024prognosisandclinical pages 1-2)
Sarcoplasmic reticulum membrane — GO:0033017 (RyR2 localization) (peltenburg2024prognosisandclinical pages 1-2)

6.4 Suggested Cell Ontology (CL) terms (examples)

Primary affected cell type is the cardiac muscle cell / cardiomyocyte (e.g., CL:0000746), as the pathophysiology centers on SR Ca2+ handling in cardiomyocytes. (peltenburg2024prognosisandclinical pages 1-2, miotto2024structuralbasisfor pages 1-2)

7. Anatomical structures affected

7.1 Organ and system level

Primary system: cardiovascular; primary organ: heart with electrophysiologic dysfunction rather than structural cardiomyopathy in typical CPVT presentation. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

7.2 Tissue/cell level

Primary tissue: cardiac muscle; primary cell type: cardiomyocytes with abnormal SR Ca2+ handling. (peltenburg2024prognosisandclinical pages 1-2)

7.3 Subcellular level

Key compartment: sarcoplasmic reticulum (SR) Ca2+ stores and the SR membrane-localized RyR2 channel complex. (peltenburg2024prognosisandclinical pages 1-2, keefe2023roleofca^2+ pages 29-34)

8. Temporal development

8.1 Onset

Most commonly in childhood/adolescence; mean onset 7–12 years in a 2024 review summary, with a majority presenting by age 20. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)

8.2 Progression/course

Course is typically episodic and trigger-dependent. However, multiple studies highlight that delayed/missed diagnosis is common and can contribute to poor outcomes. In China, pediatric CPVT showed a mean diagnostic delay of 4.3±6.6 years in a 95-patient compilation. (yan2023clinicalandgenetic pages 1-2)

9. Inheritance and population

9.1 Epidemiology

Prevalence: estimated at ~1 in 10,000 (review-level). (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
Contribution to sudden death: may account for up to ~15% of unexplained SCD in young people (review-level). (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
Autopsy-negative SUD: one review states ~12% of autopsy-negative sudden unexplained deaths in young individuals have been linked to CPVT. (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

9.2 Inheritance

RYR2-mediated CPVT is typically autosomal dominant. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)

9.3 Penetrance/expressivity

Penetrance estimates in reviews range roughly ~63–78% overall and ~75–80% for RYR2-mediated CPVT, consistent with variable expressivity and incomplete penetrance. (aggarwal2024catecholaminergicpolymorphicventricular pages 2-4)

10. Diagnostics

10.1 Clinical criteria and key tests

Exercise stress testing is the principal diagnostic modality to unmask adrenergically mediated polymorphic/bidirectional ventricular ectopy in the setting of a structurally normal heart and typically normal baseline ECG. (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2, aggarwal2024catecholaminergicpolymorphicventricular pages 6-8)
Epinephrine infusion test is an alternative when exercise testing is not feasible; one review provides a protocol (starting 0.05–0.1 mcg/kg/min titrated to 0.20 mcg/kg/min) and notes low sensitivity (28%) but high specificity (98%) relative to exercise testing, using arrhythmia induction criteria including polymorphic VT and high PVC burden. (aggarwal2024catecholaminergicpolymorphicventricular pages 6-8)

10.2 Genetic testing approach

Genetic testing for CPVT-susceptibility genes (including RYR2) is recommended for probands with a clinical CPVT diagnosis, alongside cascade screening of first-degree relatives. (aggarwal2024catecholaminergicpolymorphicventricular pages 6-8)
Because rare RYR2 variants occur in healthy individuals, recent expert discussion emphasizes careful variant adjudication and multidisciplinary review; de novo status increases pathogenic likelihood. (peltenburg2024prognosisandclinical pages 1-2)

10.3 Differential diagnosis (limited by retrieved evidence)

The retrieved texts emphasize that CPVT can be misdiagnosed as neurologic events (e.g., seizures) due to syncope and that careful arrhythmia provocation testing is needed. Detailed differential diagnosis lists were not extracted from the current evidence set. (jurisic2023catecholaminergicpolymorphicventricular pages 1-2)

11. Outcome / prognosis

11.1 Natural history severity and pre-diagnosis burden

A 2024 review summarizes substantial pre-diagnosis burden: ~30% experiencing at least one cardiac arrest and up to 80% having syncope prior to diagnosis; mortality is reported as high (30–50% by age 35 in review-level summaries). (aggarwal2024catecholaminergicpolymorphicventricular pages 8-9)

11.2 Recent cohort outcome statistics (2023–2024)

In the 2024 Korean pediatric cohort (n=23): - 5-year cardiac event-free survival: 31.2% - 10-year overall survival: 73.1% - Marked improvement in those diagnosed since 2009 (no deaths in that subgroup), consistent with evolving implementation of combination therapy and procedural adjuncts. (lee2024treatmentoutcomesin pages 1-2, lee2024treatmentoutcomesin pages 7-9)

12. Treatment

Current real-world algorithm (review-derived)

A recent treatment algorithm emphasizes lifestyle modification, first-line non-selective beta-blockade, escalation to flecainide and/or LCSD for persistent arrhythmias, and reserving ICD for the highest-risk patients or refractory cases; the same figure stratifies approaches for symptomatic vs asymptomatic individuals. (aggarwal2024catecholaminergicpolymorphicventricular media 56a4a30c)

Therapy (drug/procedure)	Mechanism/rationale	Indications/real-world use	Quantitative outcome data reported in 2024 Aggarwal review and 2024 Lee cohort	Key safety/limitations
Non-selective beta-blockers (preferred: nadolol; propranolol where nadolol unavailable)	Reduce adrenergic stimulation that precipitates RyR2-mediated diastolic SR Ca2+ leak and triggered ventricular arrhythmias	First-line, lifelong therapy for essentially all clinically affected RYR2-CPVT patients; non-selective agents preferred over beta1-selective drugs; background therapy before considering add-on flecainide, LCSD, or ICD (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12, aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)	Aggarwal review: higher arrhythmic risk with beta1-selective blockers versus nadolol, HR 2.04 in symptomatic children (p=0.002) and HR 5.8 in 216 RYR2-variant patients (p=0.001); up to 30% of patients on optimal beta-blocker therapy require additional treatment; nonadherence reported in ~15% and implicated in 60% of evening events (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12). Lee cohort: all 23 patients received beta-blockers, yet 73.9% developed cardiac events, 43.5% had aborted cardiac arrest, and 21.7% died during follow-up, showing monotherapy is often insufficient in high-risk pediatric disease (lee2024treatmentoutcomesin pages 6-7, lee2024treatmentoutcomesin pages 7-9)	Breakthrough events occur despite treatment; adherence problems are clinically important; side effects may preclude use in ~10%; selective beta-blockers were commonly used in one real-world pediatric cohort despite evidence favoring non-selective agents (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12, lee2024treatmentoutcomesin pages 6-7)
Flecainide add-on to beta-blocker	Direct antiarrhythmic effect with RyR2-related reduction of ventricular ectopy/triggered activity; used to suppress exercise-induced ventricular arrhythmias beyond sympathetic blockade	Add-on therapy when arrhythmias persist on beta-blockers or in higher-risk patients; commonly combined with beta-blockers in pediatric practice and expert treatment pathways (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12, lee2024treatmentoutcomesin pages 6-7)	Aggarwal review: randomized crossover study (n=14) found flecainide + beta-blocker superior to beta-blocker alone for exercise-induced arrhythmias, with no couplets/NSVT in the flecainide arm; multinational retrospective cohort (n=247) showed significant reduction in major arrhythmic events with adjunctive flecainide (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12, aggarwal2024catecholaminergicpolymorphicventricular pages 12-14). Lee cohort: combination beta-blocker + flecainide markedly lowered cardiac-event risk versus beta-blocker alone, HR 0.08 (95% CI 0.02-0.38; p=0.002); however, small subgroup analyses showed no significant reduction in treadmill arrhythmia score (p=0.317) or Holter PVC burden (p=0.144) (lee2024treatmentoutcomesin pages 7-9, lee2024treatmentoutcomesin pages 6-7)	Evidence for monotherapy is limited and combination therapy is generally preferred; some monitoring endpoints may not improve despite event reduction; availability varies by region (aggarwal2024catecholaminergicpolymorphicventricular pages 12-14, lee2024treatmentoutcomesin pages 9-10)
Left cardiac sympathetic denervation (LCSD)	Surgical/procedural reduction of cardiac sympathetic input to decrease catecholamine-triggered arrhythmogenesis	Adjunct for patients with persistent events or intolerance despite beta-blocker ± flecainide; may be used before or alongside ICD, including in recurrent shock scenarios; used substantially in pediatric tertiary centers (aggarwal2024catecholaminergicpolymorphicventricular pages 12-14, aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, lee2024treatmentoutcomesin pages 6-7)	Aggarwal review: in multicenter data, major cardiac events fell from 86% to 21% over median 37 months; mean annual event rate dropped 92%, from 3.4 (95% CI 3.2-3.7) to 0.5 (95% CI 0.4-0.6); among those symptomatic despite optimal medical therapy, about one-third had recurrent events (aggarwal2024catecholaminergicpolymorphicventricular pages 12-14, aggarwal2024catecholaminergicpolymorphicventricular pages 14-15). Lee cohort: LCSD performed in 15/23; Holter PVC burden fell from 0.7994% to 0.0103% (p=0.018); trend toward fewer cardiac events, univariable HR 0.26 (p≈0.055), multivariable HR 0.38 (p=0.174) (lee2024treatmentoutcomesin pages 6-7, lee2024treatmentoutcomesin pages 7-9)	Not curative; recurrence still occurs in ~1/3; procedural complications include ptosis, Horner syndrome, pneumothorax, and neuropathic pain, though often infrequent/transient (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)
Implantable cardioverter-defibrillator (ICD)	Rescue therapy for malignant ventricular arrhythmias/sudden cardiac arrest, but shocks can themselves provoke catecholamine release and further arrhythmia	Reserved for highest-risk patients, especially after aborted cardiac arrest; increasingly considered a last resort after optimized beta-blocker + flecainide + LCSD; in Lee cohort used rarely for refractory syncope/ACA despite other therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16, lee2024treatmentoutcomesin pages 6-7)	Aggarwal review: one review found 85% experienced device complications; inappropriate shocks in 20-30%; shocks failed for VT in 99% but succeeded for VF in 94%; meta-analysis showed 40% appropriate shocks, 21% inappropriate shocks, 20% electrical storms; registry data showed composite events 47% with ICD versus 15.8% without ICD (likely confounded) (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15). Additional review data reported other device-related complications in 29% (aggarwal2024catecholaminergicpolymorphicventricular pages 15-16). Lee cohort: 2/23 received ICDs; one had 2 appropriate shocks, another 1 appropriate shock, but one experienced electrical storm from inappropriate shocks and VT acceleration after shock (lee2024treatmentoutcomesin pages 6-7)	High morbidity, inappropriate shocks, electrical storms, and possible proarrhythmia; may not improve survival in observational comparisons; careful programming is required, and guideline-exempt management without ICD is increasingly accepted in selected CPVT patients (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16)
Triple therapy (nadolol + flecainide + LCSD)	Mechanistically complementary suppression of adrenergic drive, triggered activity, and sympathetic outflow	Expert-endorsed escalation strategy after sentinel sudden cardiac arrest or persistent high risk before/defaulting to ICD-only management (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)	Aggarwal review: expert opinion specifically supports "triple therapy" after a sentinel sudden cardiac arrest, reflecting contemporary shift toward aggressive combined non-device therapy before ICD dependence; no single pooled HR reported for the full triple regimen in the excerpts (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)	Evidence base is largely observational/expert-opinion; some patients still require ICD or experience recurrent events despite multimodal therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, lee2024treatmentoutcomesin pages 7-9)
Catheter ablation of triggering PVCs (adjunctive, selected cases)	Eliminates identifiable PVC triggers for polymorphic VT/VF but does not remove the underlying arrhythmogenic RyR2 substrate	Considered in selected refractory patients, especially if flecainide cannot be used or if discrete triggering PVCs are mappable; adjunct rather than core therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 16-18, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16)	Aggarwal review: trigger elimination achieved non-inducibility in >90% of patients and nearly 60% remained free from syncope during follow-up; however, recurrence remained substantial, with 80% recurrence in one 5-patient series and mean time to recurrence ~4 years (aggarwal2024catecholaminergicpolymorphicventricular pages 16-18, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16)	Does not treat the underlying disease substrate; recurrence can be high; usually requires continued consideration of LCSD/ICD in high-risk patients (aggarwal2024catecholaminergicpolymorphicventricular pages 16-18, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16)

Table: This table summarizes the main evidence-based management strategies for RYR2-mediated CPVT, integrating current review-level evidence with recent real-world pediatric cohort data. It is useful for comparing mechanism, clinical use, quantitative outcomes, and limitations across medications and procedures.

12.1 Evidence-based therapies (key quantitative findings)

Beta-blockers: non-selective agents (especially nadolol) are preferred; review-level hazard ratios suggest higher arrhythmic risk with beta1-selective blockers compared with nadolol (HR 2.04 in symptomatic children; HR 5.8 in a 216-patient RYR2 cohort). (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12)

Flecainide add-on: in the 2024 Korean pediatric cohort, beta-blocker + flecainide was associated with a large reduction in cardiac events vs beta-blocker alone (HR 0.08; 95% CI 0.02–0.38; p=0.002). (lee2024treatmentoutcomesin pages 7-9)

LCSD: multicenter observational evidence summarized in a 2024 review suggests a 92% reduction in mean annual event rate (3.4 to 0.5) and major cardiac events reduction (86% to 21% over ~37 months), with ~1/3 recurrence even on optimal medical therapy. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 12-14)

ICD: evidence summarized in a 2024 review highlights high complication and shock burdens (e.g., 20–30% inappropriate shocks; high device complication rates; electrical storms), and concern that shocks may fail for VT and can worsen arrhythmia in CPVT; ICD is increasingly framed as last-resort after optimal medical and LCSD therapy. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 15-16)

12.2 MAXO term suggestions (examples)

(Provided as ontology normalization suggestions; not validated from a MAXO database in the retrieved sources.) - Beta-adrenergic antagonist therapy — MAXO: beta blocker therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12) - Flecainide therapy — MAXO: antiarrhythmic drug therapy (aggarwal2024catecholaminergicpolymorphicventricular pages 11-12) - Left cardiac sympathetic denervation — MAXO: cardiac sympathetic denervation (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15) - Implantable cardioverter-defibrillator placement — MAXO: implantable cardioverter defibrillator implantation (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15)

12.3 Recent/experimental treatments and latest research (2023–2024)

RyR2 stabilizers (“Rycals”) and structural mechanism: 2024 structural work supports the concept of pharmacologic stabilization of RyR2 away from a leak-prone primed state, providing mechanistic grounding for RyR2-stabilizing small-molecule approaches. (miotto2024structuralbasisfor pages 1-2)

Genome editing (preclinical, 2024): AAV9-delivered, mutation-specific CRISPR/SaCas9 disruption of the mutant Ryr2 allele in R176Q/+ mice produced durable suppression of inducible ventricular arrhythmias at 6 weeks and out to 12 months, with favorable cardiac safety on serial echocardiography and histology; it also reduced Ca2+ spark frequency (e.g., from 8.0±1.6 toward 2.2±0.5 sparks/100 mm/s). (moore2024longtermefficacyand pages 6-9, moore2024longtermefficacyand pages 1-3)

13. Prevention

Secondary prevention: cascade family screening is highlighted as increasing detection of asymptomatic RYR2 variant carriers; guidance suggests these individuals often develop phenotype in the first two decades and may have low arrhythmic risk, but evidence-based monitoring/therapy timing remains limited. (peltenburg2024prognosisandclinical pages 1-2)

Tertiary prevention: optimal beta-blocker adherence, escalation to flecainide and LCSD, and cautious ICD deployment aim to prevent recurrent malignant arrhythmias and device-related harm. (aggarwal2024catecholaminergicpolymorphicventricular pages 14-15, aggarwal2024catecholaminergicpolymorphicventricular pages 11-12)

14. Other species / natural disease

No naturally occurring veterinary CPVT information was retrieved in the current evidence set.

15. Model organisms / disease models

15.1 Mammalian genetic models

Ryr2 R176Q/+ mouse model is used for CPVT mechanistic and therapeutic studies; allele-specific AAV9-CRISPR editing in this model demonstrated durable antiarrhythmic efficacy and safety signals through 12 months. (moore2024longtermefficacyand pages 1-3, moore2024longtermefficacyand pages 6-9)

15.2 Human cellular models (in vitro)

Human iPSC-cardiomyocyte models engineered to carry CPVT-linked RYR2 variants demonstrate arrhythmogenic Ca2+ handling phenotypes; for example, CRISPR-introduced RyR2-S4938F in hiPSC-CMs is associated with altered Ca2+ signaling and increased spontaneous Ca2+ sparks/transients consistent with an arrhythmogenic phenotype. (toth2023calciumsignalingconsequences pages 1-2)

Recent developments and active clinical trials (ClinicalTrials.gov)

1) SGT-501 gene therapy in CPVT (NCT07148089) - Sponsor: Solid Biosciences; Phase 1b, open-label dose-finding; Recruiting; estimated enrollment 18. - Key inclusion: central-lab confirmed pathogenic/likely pathogenic RYR2 variant and prior life-threatening ventricular arrhythmic event; stable beta-blocker and/or flecainide regimen. - Primary endpoint: treatment-emergent adverse events through Day 360; secondary endpoint includes change in ventricular arrhythmia score (VAS) on exercise stress test at Day 180. Long-term follow-up planned for 5 years. (posted/record date in excerpt: 2026-04-03). URL: https://clinicaltrials.gov/study/NCT07148089 (NCT07148089 chunk 1, NCT07148089 chunk 2)

2) S48168 (ARM210) RyR2 modulator trial in CPVT1 (NCT05122975) - Sponsor: RyCarma Therapeutics; Phase 2, randomized crossover, quadruple-masked; enrollment 8; Terminated due to recruitment challenges. - Intervention: oral S48168 (ARM210) vs placebo on top of standard of care, 28-day periods. - Primary endpoint: change in exercise ectopy score from baseline to Day 28 vs placebo; additional endpoints include safety, PK, and wearable monitoring. Start date 2023-08-01; primary completion 2024-04-01. URL: https://clinicaltrials.gov/study/NCT05122975 (NCT05122975 chunk 1)

Direct quotes from abstracts (supporting key statements)

Diagnostic hallmark and phenotype: “Diagnosing CPVT typically involves unmasking the arrhythmia through exercise stress testing… in the absence of structural heart disease… and with a normal baseline electrocardiogram.” (Aggarwal et al., 2024-03; URL https://doi.org/10.3390/jcm13061781) (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
Asymptomatic carrier management gap: asymptomatic family members with a pathogenic RYR2 variant have arrhythmic risk described as “presumably low” and phenotype “seems to develop in the first two decades of life,” with limited guidance. (Peltenburg et al., 2024-04; URL https://doi.org/10.1017/s1047951124000714) (peltenburg2024prognosisandclinical pages 1-2)
Structural mechanism: RyR2 variants “linked either to heart failure or inherited sudden cardiac death… are in the primed state… Binding of Rycal drugs… reverts the primed state back towards the closed state, decreasing Ca2+ leak… preventing arrhythmias.” (Miotto et al., 2024-09; URL https://doi.org/10.1038/s41467-024-51791-y) (miotto2024structuralbasisfor pages 1-2)

Key limitations / evidence gaps

Formal database identifiers (OMIM/Orphanet/MeSH/ICD/MONDO) were not retrievable within the current evidence set; a dedicated database lookup would be required to populate those fields with citations.
Several important quantitative claims in review articles summarize prior cohorts/meta-analyses; the underlying primary sources (often pre-2023) were not all retrieved as full text in this run, limiting direct PMID-level citation.
Differential diagnosis lists, QoL instrument data (EQ-5D/SF-36/PROMIS), and protective genetic/environmental factors were not found in the retrieved evidence.

URLs and publication dates (selected high-priority sources used)

Aggarwal et al. “Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies.” J Clin Med (2024-03). https://doi.org/10.3390/jcm13061781 (aggarwal2024catecholaminergicpolymorphicventricular pages 1-2)
Peltenburg et al. “Prognosis and clinical management of asymptomatic family members with RYR2-mediated CPVT.” Cardiol Young (2024-04). https://doi.org/10.1017/S1047951124000714 (peltenburg2024prognosisandclinical pages 1-2)
Lee et al. “Treatment outcomes in children with CPVT: a single institutional experience.” Korean Circ J (2024-12). https://doi.org/10.4070/kcj.2024.0183 (lee2024treatmentoutcomesin pages 1-2)
Yan et al. “Clinical and genetic profiles of Chinese pediatric CPVT patients.” Orphanet J Rare Dis (2023-12). https://doi.org/10.1186/s13023-023-02991-0 (yan2023clinicalandgenetic pages 1-2)
Miotto et al. “Structural basis for RyR2 leak…” Nat Commun (2024-09). https://doi.org/10.1038/s41467-024-51791-y (miotto2024structuralbasisfor pages 1-2)
Moore et al. “Long-term efficacy and safety of cardiac genome editing for CPVT.” J Cardiovasc Aging (2024-01). https://doi.org/10.20517/jca.2023.42 (moore2024longtermefficacyand pages 1-3)
ClinicalTrials.gov NCT07148089 (SGT-501 gene therapy) record excerpt date 2026-04-03. https://clinicaltrials.gov/study/NCT07148089 (NCT07148089 chunk 1)
ClinicalTrials.gov NCT05122975 (S48168/ARM210) start 2023-08-01; primary completion 2024-04-01. https://clinicaltrials.gov/study/NCT05122975 (NCT05122975 chunk 1)

References

(aggarwal2024catecholaminergicpolymorphicventricular pages 1-2): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(peltenburg2024prognosisandclinical pages 1-2): Puck J. Peltenburg, Harry Gibson, Arthur A. M. Wilde, Christian van der Werf, Sally-Ann B. Clur, and Nico A. Blom. Prognosis and clinical management of asymptomatic family members with ryr2-mediated catecholaminergic polymorphic ventricular tachycardia: a review. Cardiology in the young, 34:1-8, Apr 2024. URL: https://doi.org/10.1017/s1047951124000714, doi:10.1017/s1047951124000714. This article has 1 citations and is from a peer-reviewed journal.
(lee2024treatmentoutcomesin pages 1-2): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.
(jurisic2023catecholaminergicpolymorphicventricular pages 1-2): Stjepan Jurisic, Argelia Medeiros-Domingo, Florian Berger, Christian Balmer, Corinna Brunckhorst, Frank Ruschitzka, Ardan M. Saguner, and Firat Duru. Catecholaminergic polymorphic ventricular tachycardia: multiple clinical presentations of a genetically determined disease. Journal of Clinical Medicine, 13:47, Dec 2023. URL: https://doi.org/10.3390/jcm13010047, doi:10.3390/jcm13010047. This article has 5 citations.
(aggarwal2024catecholaminergicpolymorphicventricular pages 2-4): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(aggarwal2024catecholaminergicpolymorphicventricular pages 6-8): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(aggarwal2024catecholaminergicpolymorphicventricular pages 8-9): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(wang2024clinicalcharacteristicsand pages 7-8): Yefeng Wang, Yufan Yang, Ningan Xu, Yunbin Xiao, Chao Zuo, and Zhi Chen. Clinical characteristics and follow-up of complex arrhythmias associated with ryr2 gene mutations in children. Frontiers in Genetics, May 2024. URL: https://doi.org/10.3389/fgene.2024.1405437, doi:10.3389/fgene.2024.1405437. This article has 1 citations and is from a peer-reviewed journal.
(lee2024treatmentoutcomesin pages 7-9): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.
(yan2023clinicalandgenetic pages 1-2): Yu Yan, Liting Tang, Xiaoqin Wang, Kaiyu Zhou, Fan Hu, Hongyu Duan, Xiaoliang Liu, Yimin Hua, and Chuan Wang. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia. Orphanet Journal of Rare Diseases, Dec 2023. URL: https://doi.org/10.1186/s13023-023-02991-0, doi:10.1186/s13023-023-02991-0. This article has 4 citations and is from a peer-reviewed journal.
(yan2023clinicalandgenetic pages 2-4): Yu Yan, Liting Tang, Xiaoqin Wang, Kaiyu Zhou, Fan Hu, Hongyu Duan, Xiaoliang Liu, Yimin Hua, and Chuan Wang. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia. Orphanet Journal of Rare Diseases, Dec 2023. URL: https://doi.org/10.1186/s13023-023-02991-0, doi:10.1186/s13023-023-02991-0. This article has 4 citations and is from a peer-reviewed journal.
(aggarwal2024catecholaminergicpolymorphicventricular pages 14-15): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(aggarwal2024catecholaminergicpolymorphicventricular media 56a4a30c): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(keefe2023roleofca^2+ pages 8-9): Joshua A. Keefe, Oliver M. Moore, Kevin S. Ho, and Xander H. T. Wehrens. Role of ca^2+ in healthy and pathologic cardiac function: from normal excitation–contraction coupling to mutations that cause inherited arrhythmia. Archives of Toxicology, 97:73-92, Oct 2023. URL: https://doi.org/10.1007/s00204-022-03385-0, doi:10.1007/s00204-022-03385-0. This article has 45 citations and is from a highest quality peer-reviewed journal.
(keefe2023roleofca^2+ pages 29-34): Joshua A. Keefe, Oliver M. Moore, Kevin S. Ho, and Xander H. T. Wehrens. Role of ca^2+ in healthy and pathologic cardiac function: from normal excitation–contraction coupling to mutations that cause inherited arrhythmia. Archives of Toxicology, 97:73-92, Oct 2023. URL: https://doi.org/10.1007/s00204-022-03385-0, doi:10.1007/s00204-022-03385-0. This article has 45 citations and is from a highest quality peer-reviewed journal.
(keefe2023roleofca^2+ pages 3-4): Joshua A. Keefe, Oliver M. Moore, Kevin S. Ho, and Xander H. T. Wehrens. Role of ca^2+ in healthy and pathologic cardiac function: from normal excitation–contraction coupling to mutations that cause inherited arrhythmia. Archives of Toxicology, 97:73-92, Oct 2023. URL: https://doi.org/10.1007/s00204-022-03385-0, doi:10.1007/s00204-022-03385-0. This article has 45 citations and is from a highest quality peer-reviewed journal.
(miotto2024structuralbasisfor pages 1-2): Marco C. Miotto, Steven Reiken, Anetta Wronska, Qi Yuan, Haikel Dridi, Yang Liu, Gunnar Weninger, Carl Tchagou, and Andrew R. Marks. Structural basis for ryanodine receptor type 2 leak in heart failure and arrhythmogenic disorders. Nature Communications, Sep 2024. URL: https://doi.org/10.1038/s41467-024-51791-y, doi:10.1038/s41467-024-51791-y. This article has 40 citations and is from a highest quality peer-reviewed journal.
(aggarwal2024catecholaminergicpolymorphicventricular pages 11-12): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(lee2024treatmentoutcomesin pages 6-7): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.
(aggarwal2024catecholaminergicpolymorphicventricular pages 12-14): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(lee2024treatmentoutcomesin pages 9-10): Joowon Lee, Bo Sang Kwon, Mi Kyoung Song, Sang-Yun Lee, Jung Min Ko, Gi Beom Kim, and Eun Jung Bae. Treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia: a single institutional experience. Korean Circulation Journal, 54:853-864, Dec 2024. URL: https://doi.org/10.4070/kcj.2024.0183, doi:10.4070/kcj.2024.0183. This article has 1 citations and is from a peer-reviewed journal.
(aggarwal2024catecholaminergicpolymorphicventricular pages 15-16): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(aggarwal2024catecholaminergicpolymorphicventricular pages 16-18): Abhinav Aggarwal, Anton Stolear, Md Mashiul Alam, Swarnima Vardhan, Maxim Dulgher, Sun-Joo Jang, and Stuart W. Zarich. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. Journal of Clinical Medicine, 13:1781, Mar 2024. URL: https://doi.org/10.3390/jcm13061781, doi:10.3390/jcm13061781. This article has 27 citations.
(moore2024longtermefficacyand pages 6-9): Oliver M. Moore, Y. Aguilar-Sánchez, S. Lahiri, M. Hulsurkar, J. Navarro-Garcia, Tarah A. Word, Joshua A. Keefe, Dean Barazi, Elda Munivez, Charles T. Moore, Vaidya Parthasarathy, Jaysón M. Davidson, W. Lagor, So Hyun Park, Gang Bao, Christina Y Miyake, X. Wehrens, OM Moore, WR Lagor, Wehrens Xht, SK Lahiri, MM Hulsurkar, J. Navarro-Garcia, Tarah A. Word, JA Keefe, CT Moore, Parthasarathy Barazi D, SH Park, and CY Miyake. Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. The Journal of Cardiovascular Aging, Jan 2024. URL: https://doi.org/10.20517/jca.2023.42, doi:10.20517/jca.2023.42. This article has 11 citations.
(moore2024longtermefficacyand pages 1-3): Oliver M. Moore, Y. Aguilar-Sánchez, S. Lahiri, M. Hulsurkar, J. Navarro-Garcia, Tarah A. Word, Joshua A. Keefe, Dean Barazi, Elda Munivez, Charles T. Moore, Vaidya Parthasarathy, Jaysón M. Davidson, W. Lagor, So Hyun Park, Gang Bao, Christina Y Miyake, X. Wehrens, OM Moore, WR Lagor, Wehrens Xht, SK Lahiri, MM Hulsurkar, J. Navarro-Garcia, Tarah A. Word, JA Keefe, CT Moore, Parthasarathy Barazi D, SH Park, and CY Miyake. Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. The Journal of Cardiovascular Aging, Jan 2024. URL: https://doi.org/10.20517/jca.2023.42, doi:10.20517/jca.2023.42. This article has 11 citations.
(toth2023calciumsignalingconsequences pages 1-2): Noemi Toth, Xiao-Hua Zhang, Alexandra Zamaro, and Martin Morad. Calcium signaling consequences of ryr2-s4938f mutation expressed in human ipsc-derived cardiomyocytes. International Journal of Molecular Sciences, 24:15307, Oct 2023. URL: https://doi.org/10.3390/ijms242015307, doi:10.3390/ijms242015307. This article has 3 citations.
(NCT07148089 chunk 1): A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Solid Biosciences Inc.. 2026. ClinicalTrials.gov Identifier: NCT07148089
(NCT07148089 chunk 2): A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Solid Biosciences Inc.. 2026. ClinicalTrials.gov Identifier: NCT07148089
(NCT05122975 chunk 1): Treatment of an Inherited Ventricular Arrhythmia. RyCarma Therapeutics, Inc.. 2023. ClinicalTrials.gov Identifier: NCT05122975

Ask OpenScientist

OpenScientist Report

Inheritance

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Research report: RYR2-mediated catecholaminergic polymorphic ventricular tachycardia (RYR2-CPVT / CPVT1)

Scope and evidence types

1. Disease information

1.1 Concise overview (current understanding)

1.2 Identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

1.3 Synonyms/alternative names

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core clinical phenotype spectrum (with onset, severity, progression)

3.2 Frequency among affected individuals (recent study statistics)

3.3 Suggested HPO terms (non-exhaustive)

3.4 Quality of life impact

4. Genetic / molecular information

4.1 Causal gene(s)

4.2 Variant characteristics

4.3 Modifier genes / multiple variants

4.4 Epigenetics / chromosomal abnormalities

5. Environmental information

5.1 Environmental and lifestyle factors

5.2 Infectious agents

6. Mechanism / pathophysiology (causal chain, upstream vs downstream)

6.1 Canonical causal chain (current consensus)

6.2 Upstream modulators and structural biology (2023–2024 developments)

6.3 Suggested GO biological process / cellular component terms (examples)

6.4 Suggested Cell Ontology (CL) terms (examples)

7. Anatomical structures affected

7.1 Organ and system level

7.2 Tissue/cell level

7.3 Subcellular level

8. Temporal development

8.1 Onset

8.2 Progression/course

9. Inheritance and population

9.1 Epidemiology

9.2 Inheritance

9.3 Penetrance/expressivity

10. Diagnostics

10.1 Clinical criteria and key tests

10.2 Genetic testing approach

10.3 Differential diagnosis (limited by retrieved evidence)

11. Outcome / prognosis

11.1 Natural history severity and pre-diagnosis burden

11.2 Recent cohort outcome statistics (2023–2024)

12. Treatment

Current real-world algorithm (review-derived)